A5047569864- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Chromosomal and Genetic Variations
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Renal Transplantation Outcomes and Treatments
- Gene expression and cancer classification
- Genomic variations and chromosomal abnormalities
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Ubiquitin and proteasome pathways
- Amyloidosis: Diagnosis, Treatment, Outcomes
- DNA Repair Mechanisms
- Chemokine receptors and signaling
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer Mechanisms and Therapy
- Neutropenia and Cancer Infections
- Molecular Biology Techniques and Applications
University of Bologna
2017-2025
Istituto di Ematologia di Bologna
2021-2024
Heidelberg University
2023
University Hospital Heidelberg
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Azienda USL di Bologna
2022
Istituto Oncologico Romagnolo
2018-2019
Institute of Oncology Research
2019
March of Dimes
2017
Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining repair. This study defines incidence chromothripsis 395 newly diagnosed adult acute myeloid leukemia (AML) patients three institutions, its impact on survival genomic background. SNP 6.0 CytoscanHD Array (Affymetrix®) were performed all samples. We detected with custom algorithm 26/395 patients. Patients harboring had higher age...
Abstract The complexity of Multiple Myeloma (MM) is driven by several genomic aberrations, interacting with disease-related and/or -unrelated factors and conditioning patients’ clinical outcome. Patient’s prognosis hardly predictable, as commonly employed MM risk models do not precisely partition high- from low-risk patients, preventing the reliable recognition early relapsing/refractory patients. By a dimensionality reduction approach, here we dissect landscape large cohort newly diagnosed...
Clonal hematopoiesis of indeterminate potential (CHIP) refers to the phenomenon where a hematopoietic stem cell acquires fitness-increasing mutation(s), resulting in its clonal expansion. CHIP is frequently observed multiple myeloma (MM) patients, and it associated with worse outcome. High-throughput amplicon-based single-cell DNA sequencing was performed on circulating CD34+ cells collected from twelve MM patients before autologous transplantation (ASCT). Moreover, four longitudinal samples...
Monosomy 7 and deletion 7q are common chromosomal abnormalities in myeloid malignancies, they associated with a poor prognosis. The mechanism underlying their acquisition remains elusive. We identified cohort of 24 patients exhibiting clones different chromosome abnormalities, such as 7q, unstable derivatives (ring chromosomes or ‘naked’ centromeres), monosomy 7. designated this group having cytogenetic clonal evolution (CCE7). In some cases, CCE7 correlated disease progression, suggesting...
Abstract Aberrations on TP53 , either as deletions of chromosome 17p (del17p) or mutations, are associated with poor outcome in multiple myeloma (MM), but conventional detection methods currently use underestimate their incidence, hindering an optimal risk assessment and prognostication MM patients. We have investigated the altered status gene by SNPs array sequencing techniques a homogenous cohort 143 newly diagnosed patients, evaluated both at diagnosis first relapse: single-hit gene,...
The impact of daratumumab on CD34+ hematopoietic stem cell (HSC) mobilization has recently been a matter concern. To address this issue, we compared HSC-related outcomes in patients with multiple myeloma treated daratumumab-based quadruplets ( N = 44) and bortezomib/thalidomide/dexamethasone 50) before cyclophosphamide-based mobilization. Plerixafor was more often required the group (52% vs. 20%, p 0.002) and, despite lower total yield, retained its efficacy boosting HSC harvesting (+90%...
Long-term kinetics of antibody (Ab) and cell-mediated immune (CMI) response to full anti-SARS-CoV-2 vaccine schedule booster doses in Multiple Myeloma (MM) patients remain unclear. We prospectively evaluated Ab CMI mRNA vaccines 103 SARS-CoV-2-naïve MM (median age 66, 1 median prior line therapy) 63 health-workers. Anti-S-RBD IgG (Elecsys ® assay) were measured before vaccination after (T1), 3 (T3), 6 (T6), 9 (T9) 12 (T12) months from second dose (D2) month the introduction (T1D3). (IGRA...
Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the standard of care for unfit chemotherapy acute myeloid leukemia (AML) patients, but safety feasibility a total outpatient management have not been fully investigated. Fifty-nine AML patients with active disease received VEN HMAs. Nineteen out 59 (32.2%) first cycle inpatients, whereas 40/59 (67.8%) were treated in setting. No significant differences observed regard to incidence adverse events (AEs), including tumor...
Minimal residual disease (MRD) is commonly assessed in bone marrow (BM) aspirate. However, sample quality can impair the MRD measurement, leading to underestimated cells and false negative results. To define a reliable reproducible method for assessment of BM hemodilution, several flow cytometry (FC) strategies hemodilution evaluation have been compared.For each sample, populations with well-known distribution peripheral blood - e.g., mast (MC), immature (IG) mature granulocytes (N) studied...
Abstract In recent years, the immunoderivative (IMiD) agents have been extensively used for treatment of multiple myeloma (MM). IMiDs and their newer derivatives CRBN E3 ligase modulator bind substrate recognition adapter protein cereblon (CRBN), which has recognized as one IMiDs’ direct target proteins, it is essential therapeutic effect these agents. High expression was associated with improved clinical response in patients MM treated IMiDs, further confirming that required anti-MM...
In recent years, liquid biopsy has emerged as a promising alternative to the bone marrow (BM) examination, since it is minimally invasive technique allowing serial monitoring. Circulating multiple myeloma cells (CMMCs) enumerated using CELLSEARCH® were correlated with patients’ prognosis and measured under treatment assess their role in monitoring disease dynamics. Forty-four MM seven smouldering (SMM) patients studied. The CMMC medians at diagnosis 349 (1 39,940) 327 (range 22–2463) for...
ABSTRACT Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven receiving mainly novel treatments (between 2006 2021) in eight Italian centres. Based on biopsy, were divided into two subgroups: AL amyloidosis (70%, n = 42) other‐MGRS (30%, 18). Results Baseline characteristics follow typical manifestations disorders...
Abstract Multiple myeloma (MM) is a plasma cell (PC) disorder characterized by skeletal involvement at the time of diagnosis. Recently, cell-free DNA (cfDNA) has been proven to recapitulate heterogeneity bone marrow (BM) disease. Our aim was evaluate prognostic role cfDNA diagnosis according disease distribution, and investigate MM microenvironment inflammatory state in supplying release cfDNA. A total 162 newly diagnosed patients were screened using 18F-FDG PET/CT assessed ultra low-pass...
Human cancer arises from a population of cells that have acquired wide range genetic alterations, most which are targets therapeutic treatments or used as prognostic factors for patient's risk stratification. Among these, copy number alterations (CNAs) quite frequent. Currently, several molecular biology technologies, such microarrays, NGS and single-cell approaches to define the genomic profile tumor samples. Output data need be analyzed with bioinformatic particularly by employing...
DNA microarrays and RNA-based sequencing approaches are considered important discovery tools in clinical medicine. However, cross-platform reproducibility studies undertaken so far have highlighted that not able to accurately measure gene expression, particularly when they expressed at low levels. Here, we consider the employment of a digital PCR assay (ddPCR) validate signature previously identified by expression profile. This included ten Hedgehog (HH) pathways' genes stratify multiple...